Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Organ preservation with radiochemotherapy and consolidation chemotherapy in locally advanced rectal cancer
2024-517928-19-00Phase 2Completed
- Sponsor
- University Hospital Tübingen
- Start
- Oct 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluorouracil, oxaliplatin and folinic acid in rectal cancer, sponsored by University Hospital Tübingen. Primary endpoint: Clinical complete response rate. Started Oct 2024; status: completed.
02
Drugs
fluorouraciloxaliplatinfolinic acid
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2024-517928-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517928-19-00.